標(biāo)題: Titlebook: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays; Franz J. Hock,Michael K. Pugsley Living reference work 20220th edition [打印本頁(yè)] 作者: 惡夢(mèng) 時(shí)間: 2025-3-21 17:37
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays影響因子(影響力)
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays被引頻次
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays被引頻次學(xué)科排名
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays年度引用
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays年度引用學(xué)科排名
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays讀者反饋
書(shū)目名稱(chēng)Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays讀者反饋學(xué)科排名
作者: cogent 時(shí)間: 2025-3-22 00:03 作者: PLIC 時(shí)間: 2025-3-22 02:53 作者: alcohol-abuse 時(shí)間: 2025-3-22 05:00
Magnetic Resonance Imaging in Pharmaceutical Safety Assessment,arkers identified in preclinical safety assessment studies for use in clinical drug safety studies..Imaging technologies provide powerful insights into the biological effects of pharmaceuticals and can contribute important biomarkers that aid in the development of new therapies to treat disease.作者: CHASM 時(shí)間: 2025-3-22 08:57
Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic al-based drug delivery system is unique to the drug, peptide, or protein employed in the system. Therefore, this chapter focuses on the safety considerations along with the therapeutic efficacy offered by this evolving developing area of therapeutics.作者: 專(zhuān)橫 時(shí)間: 2025-3-22 16:34 作者: 專(zhuān)橫 時(shí)間: 2025-3-22 19:57
Distribution: Across Barriers,barrier. Meanwhile, there exist several in vitro systems to study drug permeation across this special blood–brain barrier (section “Blood–Brain Barrier (BBB)”). They cover primary cultures of brain endothelial cells in monoculture or as coculture with astrocytes or pericytes (section “Primary Cultur作者: 文字 時(shí)間: 2025-3-22 21:20
Drug Safety Assessment,. Guidelines hereby serve to optimize and facilitate development of harmonized desirable standards to optimize research and regulations, and to accelerate their implementation..The aim of this article is to summarize the complex procedures needed to create guidelines and to support their use. The ma作者: 輕信 時(shí)間: 2025-3-23 01:43 作者: Accord 時(shí)間: 2025-3-23 09:13 作者: 得體 時(shí)間: 2025-3-23 10:56
Drug Addiction and Drug Dependency,ioned place preference, and intracranial self-stimulation. This chapter outlines approaches commonly employed in studies of abuse and dependence liability assessments and highlights recent trends and advances in the utilization of each approach over the last decade.作者: 下垂 時(shí)間: 2025-3-23 14:21
Side Effects of Central Analgesic Drugs,algesics. In this chapter, we describe protocols currently used to evaluate important opioid-related centrally mediated adverse effects. These include protocols for assessing respiratory depression, sedation, constipation, physical dependence, and abuse liability using rodent and non-human primate m作者: 概觀 時(shí)間: 2025-3-23 19:08
Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays作者: Forage飼料 時(shí)間: 2025-3-24 01:21
Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays978-3-030-73317-9作者: 暗語(yǔ) 時(shí)間: 2025-3-24 03:29
Denk wat meer als een journalist, recommend the realization of supplemental safety studies in order to further evaluate the risk level on specific CNS processes. We present supplemental studies in three major safety domains including dependence/abuse, cognitive functions, and electrophysiological CNS activity.作者: dithiolethione 時(shí)間: 2025-3-24 09:03
https://doi.org/10.1007/978-90-313-9159-2 this chapter. These modifications target not just the accuracy and safety but also increase the reproducibility of the original assays. We believe this approach will give examples of the thought processes from former successful studies, thus being helpful for future researchers to adjust and update作者: 鎮(zhèn)壓 時(shí)間: 2025-3-24 11:22
Vasculaire geneeskunde in beeldnt safety pharmacology parameters into repeat-dose toxicity studies. This chapter reviews the evolution of assessment of biopharmaceuticals using examples from approval packages of marketed agents and discusses the past, current, and new approaches and methods that can be used to generate high-quali作者: intention 時(shí)間: 2025-3-24 15:03
Jacqueline de Graaf,Anton F. H. Stalenhoefarkers identified in preclinical safety assessment studies for use in clinical drug safety studies..Imaging technologies provide powerful insights into the biological effects of pharmaceuticals and can contribute important biomarkers that aid in the development of new therapies to treat disease.作者: 銀版照相 時(shí)間: 2025-3-24 19:07
Jacqueline de Graaf,Anton F. H. Stalenhoefal-based drug delivery system is unique to the drug, peptide, or protein employed in the system. Therefore, this chapter focuses on the safety considerations along with the therapeutic efficacy offered by this evolving developing area of therapeutics.作者: 自傳 時(shí)間: 2025-3-25 01:02 作者: 歡呼 時(shí)間: 2025-3-25 05:23 作者: Habituate 時(shí)間: 2025-3-25 07:42
Jacqueline de Graaf,Anton F. H. Stalenhoef. Guidelines hereby serve to optimize and facilitate development of harmonized desirable standards to optimize research and regulations, and to accelerate their implementation..The aim of this article is to summarize the complex procedures needed to create guidelines and to support their use. The ma作者: Keratectomy 時(shí)間: 2025-3-25 12:41 作者: asthma 時(shí)間: 2025-3-25 18:04 作者: Haphazard 時(shí)間: 2025-3-26 00:03 作者: 其他 時(shí)間: 2025-3-26 02:43 作者: MOCK 時(shí)間: 2025-3-26 07:45 作者: Communicate 時(shí)間: 2025-3-26 10:17 作者: 男學(xué)院 時(shí)間: 2025-3-26 15:35
Jacqueline de Graaf,Anton F. H. Stalenhoefhe concentration-time profiles of drugs and/or metabolites in man or in animals are studied so their respective pharmacokinetics can be calculated and used as a basis for the evaluation of preclinical (especially toxicological) and clinical studies.作者: 你敢命令 時(shí)間: 2025-3-26 20:16 作者: FLIT 時(shí)間: 2025-3-26 23:03 作者: NADIR 時(shí)間: 2025-3-27 03:24
Jacqueline de Graaf,Anton F. H. Stalenhoefbase run by the REACH regulator, the European Chemicals Agency (ECHA) based in Helsinki, Finland. The agency manages the databases necessary to operate the system, coordinates the in-depth evaluation of potentially hazardous chemicals, and is building a public database in which consumers and professionals can find hazard information.作者: Predigest 時(shí)間: 2025-3-27 07:26
Oncology Pharmacology,es for anticancer therapeutics has significantly different goals and required outcomes relative to nononcology therapeutics. This chapter specifically describes screening methodologies of particular relevance to oncology therapeutics, not covered in detail in other chapters.作者: 噴油井 時(shí)間: 2025-3-27 13:28
Safe Chemicals/REACH,base run by the REACH regulator, the European Chemicals Agency (ECHA) based in Helsinki, Finland. The agency manages the databases necessary to operate the system, coordinates the in-depth evaluation of potentially hazardous chemicals, and is building a public database in which consumers and professionals can find hazard information.作者: 洞穴 時(shí)間: 2025-3-27 15:59 作者: Commission 時(shí)間: 2025-3-27 18:41
Clinical Pharmacokinetic Studies, followed by studies in patient population(s) with the aim to find the relevant dose in the target population(s). Particular pharmacokinetic studies in special populations assess the necessity of a dose adjustment from the planned/established clinical dose for patients.作者: 縱火 時(shí)間: 2025-3-27 22:49 作者: 責(zé)怪 時(shí)間: 2025-3-28 04:07
Vasculaire geneeskunde in beeldtics on the cardiovascular and pulmonary systems are highlighted. However, additional information regarding the mechanisms of action of such agents is still needed, which would improve their use in terms of safety and efficacy.作者: Instantaneous 時(shí)間: 2025-3-28 09:39
Safety of Intravenous and Inhalation Anesthetics,tics on the cardiovascular and pulmonary systems are highlighted. However, additional information regarding the mechanisms of action of such agents is still needed, which would improve their use in terms of safety and efficacy.作者: 一瞥 時(shí)間: 2025-3-28 13:45
Status of Safety Pharmacology and Present Guidelines,in detail. A detailed guideline development after the more frequently observed QT-time prolongation is also described. The different strategies prior to the implementation of the ICH Guidelines are also discussed.作者: ASSAY 時(shí)間: 2025-3-28 16:02
Living reference work 20220th edition pharmacokinetic assays. Each assay description is sufficiently outlined and equipped with outstanding literature references. This comprehensive handbook mainly addresses the needs of pharmacological institutes and research groups working in this area..作者: Synchronism 時(shí)間: 2025-3-28 20:00 作者: Atheroma 時(shí)間: 2025-3-29 02:23
De theorie achter de voetreflexologieThe adverse effects of new chemical entities (NCE) in animals and humans can manifest as changes in the structural, biochemical, or physiological status of the organism (see Fig. .). In the preclinical safety assessment process, toxicological procedures have traditionally focused on the structural and biochemical consequences of drug actions.作者: 拖債 時(shí)間: 2025-3-29 06:38
Safety Pharmacology: Introduction,The adverse effects of new chemical entities (NCE) in animals and humans can manifest as changes in the structural, biochemical, or physiological status of the organism (see Fig. .). In the preclinical safety assessment process, toxicological procedures have traditionally focused on the structural and biochemical consequences of drug actions.作者: 觀點(diǎn) 時(shí)間: 2025-3-29 10:46
Franz J. Hock,Michael K. PugsleyA landmark in the continuously changing world of drugs.Essential reading for scientists and managers involved in drug finding, drug development and decision making.Of use for government institutions a作者: FLINT 時(shí)間: 2025-3-29 15:19 作者: Daily-Value 時(shí)間: 2025-3-29 19:04 作者: 笨拙的我 時(shí)間: 2025-3-29 22:13 作者: Bumble 時(shí)間: 2025-3-30 00:49 作者: 成績(jī)上升 時(shí)間: 2025-3-30 04:38 作者: SOB 時(shí)間: 2025-3-30 11:25
Vasculaire geneeskunde in beelds, hormones, enzymes, cytokines, and growth factors that are used to diagnose, treat, or prevent various diseases. Safety pharmacology assessment of biopharmaceuticals has evolved since the approval of the first example (recombinant human insulin) in 1982. This evolution is ongoing and is informed b作者: Amenable 時(shí)間: 2025-3-30 14:31
Jacqueline de Graaf,Anton F. H. Stalenhoefor a response to a therapeutic intervention. A quantitative imaging biomarker is measured on a ratio scale or interval scale, which makes them more suited to studies with follow-up after an intervention. Tissue properties such as tissue microstructure, composition, metabolism, function, and gross mo作者: 多骨 時(shí)間: 2025-3-30 19:22 作者: biopsy 時(shí)間: 2025-3-31 00:10
Jacqueline de Graaf,Anton F. H. Stalenhoeftered systemically for acute emergency situations. As injectable drug technologies developed, it was soon observed that drug administration would often be more effective if given in sustained release or tailored release profiles. However, the potential safety risks of drugs administered by these nov作者: 根除 時(shí)間: 2025-3-31 02:57
Jacqueline de Graaf,Anton F. H. Stalenhoefy industrial chemicals are regulated in the European Economic Area (EEA). It harmonizes the control of chemicals placed on the European market and replaces a large number of European and national regulations with a single legal framework. One of the major changes established by the REACH regulation 作者: Deadpan 時(shí)間: 2025-3-31 08:16
Vasculaire geneeskunde in beeldhe term “safety pharmacology” as an applied field of pharmacology but also defined the core battery requirements for all new pharmaceuticals entering human trials. The primary objective of the safety pharmacology core battery studies is to protect clinical trial participants and patients from potent作者: 離開(kāi)就切除 時(shí)間: 2025-3-31 11:29
Jacqueline de Graaf,Anton F. H. Stalenhoefd International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidance requires that the concentration-time profiles of drugs and/or metabolites in man or in animals are studied so their respective pharmacokinetics can be calculated and作者: 清醒 時(shí)間: 2025-3-31 13:58 作者: 不確定 時(shí)間: 2025-3-31 19:33
Jacqueline de Graaf,Anton F. H. Stalenhoefon, metabolism, and excretion over time are assessed. In the early clinical development, the pharmacokinetics of a drug is studied in healthy subjects followed by studies in patient population(s) with the aim to find the relevant dose in the target population(s). Particular pharmacokinetic studies i作者: LAY 時(shí)間: 2025-3-31 23:20
Jacqueline de Graaf,Anton F. H. Stalenhoefriments, the analysis of data, and their extrapolation to humans constitute a prerequisite for the development of effective, safe, and high-quality pharmaceuticals. The enormous complexity of activities bears the risk that individual researchers deviate from the traditional or recommended path. This作者: V切開(kāi) 時(shí)間: 2025-4-1 05:48
Vasculaire geneeskunde in beeldon the heart and peripheral vasculature as well as assess any other effect that may secondarily lead to an activation or depression of cardiovascular performance. According to the cardiovascular SP guidelines, telemetry studies in conscious large animals are preferred for evaluation of drug-induced 作者: embolus 時(shí)間: 2025-4-1 06:40 作者: Cabg318 時(shí)間: 2025-4-1 11:06 作者: 盤(pán)旋 時(shí)間: 2025-4-1 16:15
Jacqueline de Graaf,Anton F. H. Stalenhoefoften included in comprehensive drug safety evaluation programs. Many abuse-related effects of drugs have been modeled in laboratory animals using well-established and validated procedures both to study the underlying neurobiological and behavioral phenomena associated with drug abuse and to assess
